Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation
Abstract:Elovaara I, Kuusisto H, Paalavuo R, Särkijärvi S, Lehtimäki T, Huhtala H, Vilpo J. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation.
Acta Neurol Scand 2006: 113: 163–166 © 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard. Objectives –
Therapy of acute exacerbations of multiple sclerosis (MS) with high-dose intravenous methylprednisolone (IVMP) has shortened the recovery period after relapses, but the mechanisms responsible for the beneficial effects of IVMP in attacks have not been clearly established. Our purpose was to analyze the effect of IVMP on the expression of chemokine receptor 5 (CCR5) protein in blood in acute MS exacerbation. Materials and methods –
Blood samples were collected from 10 patients with an acute MS exacerbation and the levels of CCR5 on CD4+ and CD8+ T cells and CD14+ monocytes were analyzed by using flow cytometry before IVMP, 24 h, 1 and 3 weeks after commencement of treatment. Results –
During the 3-week period the percentages of CCR5-expressing CD4+ T cells and CD8+ T cells tended to decrease (P = 0.09 and 0.05, respectively), but the effect did not reach statistical significance. No marked changes were found in the percentage of CCR5-expressing CD14+ cells. Conclusions –
A tendency to a reduction of CCR5-expressing CD4+ and CD8+ blood cells induced by IVMP suggests inhibition of their potential to transmigrate into the central nervous system, which is consistent with the short-term beneficial effect of IVMP in acute exacerbation of MS.
Document Type: Research Article
Affiliations: 1: Department of Neurology, Tampere University Hospital, Tampere, Finland 2: Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland 3: School of Public Health, University of Tampere, Finland 4: Medical School, University of Tampere, Tampere, Finland
Publication date: March 1, 2006